On February 18, 2026, Avenue Therapeutics, Inc. entered into a license agreement with Duke University for the development and commercialization of ATX-04, agreeing to an upfront payment and milestone payments based on product development. This agreement aims to treat lysosomal storage diseases, focusing initially on Pompe disease.